Molecular Biology Reports

, Volume 40, Issue 1, pp 449–455 | Cite as

Interleukin-6 gene −174G>C and −636G>C promoter polymorphisms and prostate cancer risk

  • J. F. Magalhães
  • A. J. Cortinhas
  • C. M. Albuquerque
  • C. S. Baptista
  • R. Ribeiro
  • Carlos Viegas
  • Augusto Matos
  • João Machado
  • Maria A. Pires
  • Henrique Guedes-Pinto
  • A. Martins-Bessa
  • J. C. Leitão
  • E. Bastos


Prostate cancer (PCa) is one of the most commonly diagnosed internal malignancies affecting men. Due to the important roles of IL-6 in different physiological and pathophysiological processes, IL-6 polymorphisms may modulate PCa risk. IL-6 −174 G>C (rs 1800795, also designated −236 G>C) and −636 G>C (rs 1800796, also designated −572 G>C) promoter polymorphisms have been implicated in PCa susceptibility, albeit still controversial. A literature search using PubMed and Highwire databases was conducted, resulting in eight case–control studies concerning the IL-6 −174 G>C polymorphism (11,613 PCa cases and 13,992 controls) and four case–control publications regarding the IL-6 −636 G>C polymorphism (1,941 PCa cases and 3,357 controls). In order to derive a more precise estimation, a meta-analysis based upon these selected case–control studies was performed. There was no significant association between IL-6 −174 G>C polymorphism and PCa increased risk. Nevertheless, the presence of allele C and the CC genotype were statistically significantly associated with decreased PCa risk in the overall analysis for IL-6 −636 G>C polymorphism. Additional studies in larger samples and analyses of functional repercussions of these SNPs in prostate tumor cells are necessary to validate these findings.


Interleukin-6 Polymorphism Prostate cancer Risk 

Supplementary material

11033_2012_2079_MOESM1_ESM.docx (729 kb)
Supplementary material 1 (DOCX 729 kb)
11033_2012_2079_MOESM2_ESM.docx (564 kb)
Supplementary material 2 (DOCX 563 kb)


  1. 1.
    Baade PD, Youlden DR, Kmjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53(2):171–184PubMedCrossRefGoogle Scholar
  2. 2.
    Schulz WA, Burchardt M, Cronauer MV (2003) Molecular biology of prostate cancer. Mol Hum Reprod 9(8):437–448. doi: 10.1093/molehr/gag064 PubMedCrossRefGoogle Scholar
  3. 3.
    Hughes C, Murphy A, Martin C, Sheils O, O′Leary J (2005) Molecular pathology of prostate cancer. J Clin Pathol 58(7):673–684. doi: 10.1136/jcp.2002.003954 PubMedCrossRefGoogle Scholar
  4. 4.
    Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24(18):1967–2000. doi: 10.1101/gad.1965810 PubMedCrossRefGoogle Scholar
  5. 5.
    Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC (2005) Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174(2):753–756. doi: 10.1097/01.ju.0000168723.42824.40 PubMedCrossRefGoogle Scholar
  6. 6.
    Culig Z, Puhr M (2011) Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol. doi: 10.1016/j.mce.2011.05.033
  7. 7.
    Xu B, Niu XB, Wang ZD, Cheng W, Tong N, Mi YY, Min ZC, Tao J, Li PC, Zhang W, Wu HF, Zhang ZD, Wang ZJ, Hua LX, Feng NH, Wang XR (2011) IL-6 −174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 38(4):2589–2596. doi: 10.1007/s11033-010-0399-1 PubMedCrossRefGoogle Scholar
  8. 8.
    Pierce BL, Biggs ML, DeCambre M, Reiner AP, Li C, Fitzpatrick A, Carlson CS, Stanford JL, Austin MA (2009) C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 20(7):1193–1203. doi: 10.1007/s10552-009-9320-4 PubMedCrossRefGoogle Scholar
  9. 9.
    Morgan L, Cooper J, Montgomery H, Kitchen N, Humphries SE (2006) The interleukin-6 gene −174G>C and −572G>C promoter polymorphisms are related to cerebral aneurysms. J Neurol Neurosurg Psychiatry 77(8):915–917. doi: 10.1136/jnnp.2005.081976 PubMedCrossRefGoogle Scholar
  10. 10.
    Sun J, Hedelin M, Zheng SL, Adami HO, Bensen J, Augustsson-Balter K, Chang B, Adolfsson J, Adams T, Turner A, Meyers DA, Isaacs WB, Xu J, Gronberg H (2004) Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol Biomark Prev 13(10):1677–1679Google Scholar
  11. 11.
    Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB (2006) Genetic polymorphisms of Interleukin-1B(IL-1B), IL-6, IL-8 and IL-10 and risk of prostate cancer. Cancer Res 66(8):4525–4530. doi: 1158/0008-5472.CAN-05-3987 PubMedCrossRefGoogle Scholar
  12. 12.
    Bao S, Yang W, Zhou S, Ye Z (2008) Relationship between single nucleotide polymorphisms in −174G/C and −634C/G promoter region of interleukin-6 and prostate cancer. J Huazhong Univ Sci Technol 28(6):693–696. doi: 10.1007/s11596-008-0618-3 CrossRefGoogle Scholar
  13. 13.
    Kesarwani P, Ahirwar DK, Mandhani A, Mittal RD (2008) Association between −174 G/C promoter polymorphism of the Interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol 27(9):505–509. doi: 10.1089/dna.2008.0742 PubMedCrossRefGoogle Scholar
  14. 14.
    Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, Ahn J, Mayne ST, Yu H, Peters U, Gunter MJ (2009) Adipokine genes and prostate cancer risk. Int J Cancer 124(4):869–876. doi: 10.1002/ijc.24043 PubMedCrossRefGoogle Scholar
  15. 15.
    Wang M, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA (2009) Association of IL-10 and other immune response–and obesity-related genes with prostate cancer in CLUE II. Prostate 69(8):874–885. doi: 10.1002/pros.20933 PubMedCrossRefGoogle Scholar
  16. 16.
    Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC (2009) Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis 30(8):1358–1362. doi: 10.1093/carcin/bgp124 PubMedCrossRefGoogle Scholar
  17. 17.
    Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannuci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Marchand LL, Lund E, Peeters PHM, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler G, Cox DG (2010) PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium. Carcinogenesis 31(3):455–461. doi: 10.1093/carcin/bgp307 PubMedCrossRefGoogle Scholar
  18. 18.
    Howell WM, Rose-Zerilli MJ (2007) Cytokine gene polymorphisms, cancer susceptibility and prognosis. J Nutr 137:194–199Google Scholar
  19. 19.
    Ahn HM, Park IS, Hong SJ, Hong YM (2011) Interleukin-6 (−636C/G) gene polymorphism in Korean children with Kawasaki Disease. Korean Soc Cardiol 41(6):321–325. doi: 104070/kcj.2011.41.6.321 Google Scholar
  20. 20.
    Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7):1369–1376. doi: 10.1172/JCI2629 PubMedCrossRefGoogle Scholar
  21. 21.
    Kishimoto T (2005) Interleukin-6: from basic science to medicine. Annu Rev Immunol 23:1–21. doi: 10.1146/annurev.immunol.23.021704.115806 PubMedCrossRefGoogle Scholar
  22. 22.
    Terakawa T, Miyake H, Furukawa J, Ettinger SL, Gleave ME, Fujisawa M (2009) Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer 101:1731–1739. doi: 10.1038/sj.bjc.6605358 PubMedCrossRefGoogle Scholar
  23. 23.
    Lyman GH, Kuderer NM (2005) The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 5(14):1–17. doi: 10.1186/1471-2288-5-14 Google Scholar
  24. 24.
    Walker E, Hernandez AV, Kattan MW (2008) Meta-analysis: its strengths and limitations. Cleve Clin J Med 75(6):431–439. doi: 10.3949/ccjm.75.6.431 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • J. F. Magalhães
    • 1
  • A. J. Cortinhas
    • 2
  • C. M. Albuquerque
    • 1
  • C. S. Baptista
    • 1
    • 3
  • R. Ribeiro
    • 4
  • Carlos Viegas
    • 6
    • 7
  • Augusto Matos
    • 8
    • 9
  • João Machado
    • 6
  • Maria A. Pires
    • 6
    • 10
  • Henrique Guedes-Pinto
    • 1
  • A. Martins-Bessa
    • 5
  • J. C. Leitão
    • 2
  • E. Bastos
    • 1
  1. 1.Centre of Genomics and Biotechnology, Institute for Biotechnology and BioengineeringUniversity of Trás-os-Montes and Alto Douro (CGB-UTAD/IBB), Quinta dos PradosVila RealPortugal
  2. 2.Research Center in Sports Sciences, Health Sciences and Human Development (CIDESD)University of Trás-os-Montes and Alto DouroVila RealPortugal
  3. 3.Multidisciplinary Unit for Biomedical Research, Institute of Biomedical Sciences Abel SalazarUniversity of Porto (ICBAS-UMIB-UP)PortoPortugal
  4. 4.Molecular Oncology Group—CI, Portuguese Institute of Oncology, Porto CentreRua Dr. António Bernardino AlmeidaPortoPortugal
  5. 5.Department of Veterinary Sciences, CECAV—Agricultural and Veterinary Sciences SchoolUniversity of Trás-os-Montes and Alto Douro, Quinta dos PradosVila RealPortugal
  6. 6.Department of Veterinary Sciences, School of Agriculture and Veterinary SciencesUniversity of Trás-os-Montes and Alto Douro (UTAD)Vila RealPortugal
  7. 7.3Bs, University of MinhoGuimarãesPortugal
  8. 8.Multidisciplinary Unit for Biomedical Research (UMIB)University of PortoPortoPortugal
  9. 9.Department of Veterinary Clinics, Institute of Biomedical Sciences Abel Salazar (ICBAS)University of Porto (ICBAS-UP)PortoPortugal
  10. 10.Department of Veterinary Sciences, CECAV—Veterinary and Animal Research CentreUniversity of Trás-os-Montes and Alto Douro (UTAD)Vila RealPortugal

Personalised recommendations